Biohaven Pharmaceutical transferred with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan took over coverage of Biohaven Pharmaceutical with an Overweight rating and $55 price target. The analyst sees Biohaven’s rimegepant in acute migraine as the key driver of shareholder value.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.